Carrying out intended dosing regimens often require highly concentrated protein formulations that may be too viscous for subcutaneous administration or other routes of administration that are limited by volume. While reducing viscosity with a single excipient can be ineffective or compromising protein stability, our platform featuring combinations of viscosity-reducing agents provides a variety of manufacturing and final formulation benefits.
Our Viscosity Reduction Platform enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing.
Our offering comprises:
The Viscosity Reduction Platform comprises six excipients from two functional groups, an amino acid component (L-Arginine, L-Phenylalanine, L-Ornithine monohydrochloride) and an anionic component (Benzenesulfonic acid, Pyridoxine hydrochloride, Thiamine phosphoric acid ester chloride dihydrate). These two components can act in synergy, leading to a superior viscosity reduction in many cases, compared to a single excipient, whilst maintaining protein stability.
The six excipients can be combined in up to nine functional combinations. As every protein is different, it is important to test to find your most promising combination.
Below are the options we offer to test the platform in order to find your most promising combination.
Save material and time during in-house screening with the excipient finder, a web application accessible upon request:
Do you have a viscosity issue but no resources to test the platform? We offer support via our Feasibility Testing Service:
The result: subcutaneous administration of protein-based therapeutics to improve patient compliance and help avoid hospitalization.
Get guidance through the challenges and quality requirements of your bio-manufacturing process.
Review a principle procedure to prepare a low volume of a highly concentrated protein formulation to allow for viscosity measurements.
Learn about strategies for reducing the viscosity of high concentration drug formulations.
Read about the effect of protein viscosity on injection force and the platform’s ability to balance viscosity reduction with protein stability
Learn how the use of viscosity-reducing excipients can improve process economics.
Read about benefits of viscosity-reducing excipients on productivity and final concentrations.
Get details on the impact of TFF cassette design & benefits of viscosity-reducing excipient combinations during TFF.
About current issues with viscosity and injectable drugs, why viscosity has become a bigger concern today than in the past, and the approach to overcoming key limitations
About current viscosity formulation challenges, the application of the Viscosity Reduction Platform, and benefits of the Feasibility Testing Service
About our scientists’ work on high concentration protein therapeutics and their viscosity, and what the solutions could mean for patients and their medicines
To continue reading please sign in or create an account.Don't Have An Account?